Skip to main content

Table 3 Comparison of RAS-positive and BRAF-positive papillary thyroid cancers

From: The variable phenotype and low-risk nature of RAS-positive thyroid nodules

Mutation

Positive predictive value (test specificity)

Tumor size (cm)

Histological subtype

Lymphovascular invasion

Extrathyroidal extension

Lymph node metastases

RAS-positive cancers (n = 8)

47 % (97.3 %)

Range: 1.0–3.6 Median: 1.9

8 – follicular variant PTC

0/8 (0 %)

0/8 (0 %)

0/8 (0 %)

BRAF-positive cancers (n = 8a)

100 % (100 %)

Range: 1.0–4.8 Median: 1.4

6 – classical variant PTCb 1 – tall cell variant PTC 1 – follicular variant PTC

5/8 (62.5 %)

1/8 (12.5 %)

1/8 (12.5 %)

  1. aNine BRAF mutations were detected in the cohort. However, one patient did not pursue surgery because of other medical conditions. Therefore eight BRAF-positive cases are shown; bincluding two classical variant PTCs with tall cell features. PTC, papillary thyroid carcinoma